Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Howard Lee Weiner, M.D.

Co-Author

This page shows the publications co-authored by Howard Weiner and David Hafler.
Connection Strength

5.777
  1. Hafler DA, Weiner HL. Immunologic mechanisms and therapy in multiple sclerosis. Immunol Rev. 1995 Apr; 144:75-107.
    View in: PubMed
    Score: 0.170
  2. Weiner HL, Hohol MJ, Khoury SJ, Dawson DM, Hafler DA. Therapy for multiple sclerosis. Neurol Clin. 1995 Feb; 13(1):173-96.
    View in: PubMed
    Score: 0.168
  3. Hafler DA, Weiner HL. Antigen specific therapies for the treatment of autoimmune diseases. Agents Actions Suppl. 1995; 47:59-77.
    View in: PubMed
    Score: 0.167
  4. Hafler DA, Weiner HL. Antigen-specific immunosuppression: oral tolerance for the treatment of autoimmune disease. Chem Immunol. 1995; 60:126-49.
    View in: PubMed
    Score: 0.167
  5. Hafler DA, Weiner HL. Antigen-specific therapies for the treatment of autoimmune diseases. Springer Semin Immunopathol. 1995; 17(1):61-76.
    View in: PubMed
    Score: 0.167
  6. Weiner HL, Friedman A, Miller A, Khoury SJ, al-Sabbagh A, Santos L, Sayegh M, Nussenblatt RB, Trentham DE, Hafler DA. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol. 1994; 12:809-37.
    View in: PubMed
    Score: 0.156
  7. Weiner HL, Mackin GA, Matsui M, Orav EJ, Khoury SJ, Dawson DM, Hafler DA. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 1993 Feb 26; 259(5099):1321-4.
    View in: PubMed
    Score: 0.147
  8. Hafler DA, Cohen I, Benjamin DS, Weiner HL. T cell vaccination in multiple sclerosis: a preliminary report. Clin Immunol Immunopathol. 1992 Mar; 62(3):307-13.
    View in: PubMed
    Score: 0.137
  9. Hafler DA, Matsui M, Wucherpfennig KW, Ota K, Weiner HL. The potential of restricted T cell recognition of myelin basic protein epitopes in the therapy of multiple sclerosis. Ann N Y Acad Sci. 1991 Dec 30; 636:251-65.
    View in: PubMed
    Score: 0.136
  10. Hafler DA, Orav J, Gertz R, Stazzone L, Weiner HL. Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis. J Neuroimmunol. 1991 May; 32(2):149-58.
    View in: PubMed
    Score: 0.130
  11. Hafler DA, Chofflon M, Kurt-Jones E, Weiner HL. Interleukin-1 corrects the defective autologous mixed lymphocyte response in multiple sclerosis. Clin Immunol Immunopathol. 1991 Jan; 58(1):115-25.
    View in: PubMed
    Score: 0.127
  12. Hafler DA, Weiner HL. MS: a CNS and systemic autoimmune disease. Immunol Today. 1989 Mar; 10(3):104-7.
    View in: PubMed
    Score: 0.111
  13. De Jager PL, Baecher-Allan C, Maier LM, Arthur AT, Ottoboni L, Barcellos L, McCauley JL, Sawcer S, Goris A, Saarela J, Yelensky R, Price A, Leppa V, Patterson N, de Bakker PI, Tran D, Aubin C, Pobywajlo S, Rossin E, Hu X, Ashley CW, Choy E, Rioux JD, Pericak-Vance MA, Ivinson A, Booth DR, Stewart GJ, Palotie A, Peltonen L, Dubois B, Haines JL, Weiner HL, Compston A, Hauser SL, Daly MJ, Reich D, Oksenberg JR, Hafler DA. The role of the CD58 locus in multiple sclerosis. Proc Natl Acad Sci U S A. 2009 Mar 31; 106(13):5264-9.
    View in: PubMed
    Score: 0.111
  14. Hafler DA, Brod SA, Weiner HL. Immunoregulation in multiple sclerosis. Res Immunol. 1989 Feb; 140(2):233-9; discussion 245-8.
    View in: PubMed
    Score: 0.111
  15. Hafler DA, Ritz J, Schlossman SF, Weiner HL. Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses. J Immunol. 1988 Jul 01; 141(1):131-8.
    View in: PubMed
    Score: 0.106
  16. Hafler DA, Weiner HL. Immunosuppression with monoclonal antibodies in multiple sclerosis. Neurology. 1988 Jul; 38(7 Suppl 2):42-7.
    View in: PubMed
    Score: 0.106
  17. De Jager PL, Rossin E, Pyne S, Tamayo P, Ottoboni L, Viglietta V, Weiner M, Soler D, Izmailova E, Faron-Yowe L, O'Brien C, Freeman S, Granados S, Parker A, Roubenoff R, Mesirov JP, Khoury SJ, Hafler DA, Weiner HL. Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain. 2008 Jul; 131(Pt 7):1701-11.
    View in: PubMed
    Score: 0.106
  18. Vaknin-Dembinsky A, Murugaiyan G, Hafler DA, Astier AL, Weiner HL. Increased IL-23 secretion and altered chemokine production by dendritic cells upon CD46 activation in patients with multiple sclerosis. J Neuroimmunol. 2008 Mar; 195(1-2):140-5.
    View in: PubMed
    Score: 0.105
  19. Hafler DA, Duby AD, Lee SJ, Benjamin D, Seidman JG, Weiner HL. Oligoclonal T lymphocytes in the cerebrospinal fluid of patients with multiple sclerosis. J Exp Med. 1988 Apr 01; 167(4):1313-22.
    View in: PubMed
    Score: 0.105
  20. Weiner HL, Hafler DA. Immunotherapy of multiple sclerosis. Ann Neurol. 1988 Mar; 23(3):211-22.
    View in: PubMed
    Score: 0.104
  21. Hafler DA, Weiner HL. Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human antimouse responses. Ann N Y Acad Sci. 1988; 540:557-9.
    View in: PubMed
    Score: 0.103
  22. Hafler DA, Weiner HL. T cells in multiple sclerosis and inflammatory central nervous system diseases. Immunol Rev. 1987 Dec; 100:307-32.
    View in: PubMed
    Score: 0.102
  23. Hafler DA, Fox DA, Benjamin D, Blue ML, Weiner HL. Secondary immune amplification following live poliovirus immunization in humans. Clin Immunol Immunopathol. 1987 Sep; 44(3):321-8.
    View in: PubMed
    Score: 0.100
  24. Hafler DA, Benjamin DS, Burks J, Weiner HL. Myelin basic protein and proteolipid protein reactivity of brain- and cerebrospinal fluid-derived T cell clones in multiple sclerosis and postinfectious encephalomyelitis. J Immunol. 1987 Jul 01; 139(1):68-72.
    View in: PubMed
    Score: 0.099
  25. Hafler DA, Weiner HL. In vivo labeling of blood T cells: rapid traffic into cerebrospinal fluid in multiple sclerosis. Ann Neurol. 1987 Jul; 22(1):89-93.
    View in: PubMed
    Score: 0.099
  26. Karni A, Abraham M, Monsonego A, Cai G, Freeman GJ, Hafler D, Khoury SJ, Weiner HL. Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol. 2006 Sep 15; 177(6):4196-202.
    View in: PubMed
    Score: 0.094
  27. Hafler DA, Fox DA, Benjamin D, Weiner HL. Antigen reactive memory T cells are defined by Ta1. J Immunol. 1986 Jul 15; 137(2):414-8.
    View in: PubMed
    Score: 0.093
  28. Hafler DA, Fallis RJ, Dawson DM, Schlossman SF, Reinherz EL, Weiner HL. Immunologic responses of progressive multiple sclerosis patients treated with an anti-T-cell monoclonal antibody, anti-T12. Neurology. 1986 Jun; 36(6):777-84.
    View in: PubMed
    Score: 0.092
  29. Hafler DA, Johnson D, Kelly JJ, Panitch H, Kyle R, Weiner HL. Monoclonal gammopathy and neuropathy: myelin-associated glycoprotein reactivity and clinical characteristics. Neurology. 1986 Jan; 36(1):75-8.
    View in: PubMed
    Score: 0.090
  30. Hafler DA, Hemler ME, Christenson L, Williams JM, Shapiro HM, Strom TB, Strominger JL, Weiner HL. Investigation of in vivo activated T cells in multiple sclerosis and inflammatory central nervous system diseases. Clin Immunol Immunopathol. 1985 Nov; 37(2):163-71.
    View in: PubMed
    Score: 0.088
  31. Hafler DA, Buchsbaum M, Johnson D, Weiner HL. Phenotypic and functional analysis of T cells cloned directly from the blood and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol. 1985 Oct; 18(4):451-8.
    View in: PubMed
    Score: 0.088
  32. Hafler DA, Buchsbaum M, Weiner HL. Decreased autologous mixed lymphocyte reaction in multiple sclerosis. J Neuroimmunol. 1985 Oct; 9(6):339-47.
    View in: PubMed
    Score: 0.088
  33. Hafler DA, Fox DA, Manning ME, Schlossman SF, Reinherz EL, Weiner HL. In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. N Engl J Med. 1985 May 30; 312(22):1405-11.
    View in: PubMed
    Score: 0.086
  34. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med. 2004 Apr 05; 199(7):971-9.
    View in: PubMed
    Score: 0.079
  35. Hohol MJ, Olek MJ, Orav EJ, Stazzone L, Hafler DA, Khoury SJ, Dawson DM, Weiner HL. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler. 1999 Dec; 5(6):403-9.
    View in: PubMed
    Score: 0.059
  36. Windhagen A, Anderson DE, Carrizosa A, Balashov K, Weiner HL, Hafler DA. Cytokine secretion of myelin basic protein reactive T cells in patients with multiple sclerosis. J Neuroimmunol. 1998 Nov 02; 91(1-2):1-9.
    View in: PubMed
    Score: 0.054
  37. Takashima H, Smith DR, Fukaura H, Khoury SJ, Hafler DA, Weiner HL. Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen-specific IL-4-secreting T cells in multiple sclerosis patients. Clin Immunol Immunopathol. 1998 Jul; 88(1):28-34.
    View in: PubMed
    Score: 0.053
  38. Hafler DA, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Fukaura H. Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis. Ann N Y Acad Sci. 1997 Dec 19; 835:120-31.
    View in: PubMed
    Score: 0.051
  39. Smith DR, Balashov KE, Hafler DA, Khoury SJ, Weiner HL. Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann Neurol. 1997 Sep; 42(3):313-8.
    View in: PubMed
    Score: 0.050
  40. Kent SC, Fukaura H, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA. Oral administration of myelin induces antigen-specific TGF-beta 1-secreting T cells in multiple sclerosis patients. Ann N Y Acad Sci. 1997 Apr 05; 815:412-22.
    View in: PubMed
    Score: 0.049
  41. Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL. Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A. 1997 Jan 21; 94(2):599-603.
    View in: PubMed
    Score: 0.048
  42. Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA. Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest. 1996 Jul 01; 98(1):70-7.
    View in: PubMed
    Score: 0.046
  43. Keshavan A, Paul F, Beyer MK, Zhu AH, Papinutto N, Shinohara RT, Stern W, Amann M, Bakshi R, Bischof A, Carriero A, Comabella M, Crane JC, D'Alfonso S, Demaerel P, Dubois B, Filippi M, Fleischer V, Fontaine B, Gaetano L, Goris A, Graetz C, Gröger A, Groppa S, Hafler DA, Harbo HF, Hemmer B, Jordan K, Kappos L, Kirkish G, Llufriu S, Magon S, Martinelli-Boneschi F, McCauley JL, Montalban X, Mühlau M, Pelletier D, Pattany PM, Pericak-Vance M, Cournu-Rebeix I, Rocca MA, Rovira A, Schlaeger R, Saiz A, Sprenger T, Stecco A, Uitdehaag BMJ, Villoslada P, Wattjes MP, Weiner H, Wuerfel J, Zimmer C, Zipp F, Hauser SL, Oksenberg JR, Henry RG. Power estimation for non-standardized multisite studies. Neuroimage. 2016 07 01; 134:281-294.
    View in: PubMed
    Score: 0.046
  44. Hohol MJ, Khoury SJ, Cook SL, Orav EJ, Hafler DA, Weiner HL. Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of a phase III pivotal trial. Ann N Y Acad Sci. 1996 Feb 13; 778:243-50.
    View in: PubMed
    Score: 0.045
  45. Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA. Antigen-specific TGF-beta1 secretion with bovine myelin oral tolerization in multiple sclerosis. Ann N Y Acad Sci. 1996 Feb 13; 778:251-7.
    View in: PubMed
    Score: 0.045
  46. Matsui M, Hafler DA, Weiner HL. Pilot study of oral tolerance to keyhole limpet hemocyanin in humans: down-regulation of KLH-reactive precursor-cell frequency. Ann N Y Acad Sci. 1996 Feb 13; 778:398-404.
    View in: PubMed
    Score: 0.045
  47. Windhagen A, Nicholson LB, Weiner HL, Kuchroo VK, Hafler DA. Role of Th1 and Th2 cells in neurologic disorders. Chem Immunol. 1996; 63:171-86.
    View in: PubMed
    Score: 0.045
  48. Balashov KE, Khoury SJ, Hafler DA, Weiner HL. Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis. J Clin Invest. 1995 Jun; 95(6):2711-9.
    View in: PubMed
    Score: 0.043
  49. Chen Y, Kuchroo VK, Inobe J, Hafler DA, Weiner HL. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science. 1994 Aug 26; 265(5176):1237-40.
    View in: PubMed
    Score: 0.041
  50. Kuchroo VK, Collins M, al-Sabbagh A, Sobel RA, Whitters MJ, Zamvil SS, Dorf ME, Hafler DA, Seidman JG, Weiner HL, et al. T cell receptor (TCR) usage determines disease susceptibility in experimental autoimmune encephalomyelitis: studies with TCR V beta 8.2 transgenic mice. J Exp Med. 1994 May 01; 179(5):1659-64.
    View in: PubMed
    Score: 0.040
  51. Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med. 1994 Mar 01; 179(3):973-84.
    View in: PubMed
    Score: 0.039
  52. Ottoboni L, Frohlich IY, Lee M, Healy BC, Keenan BT, Xia Z, Chitnis T, Guttmann CR, Khoury SJ, Weiner HL, Hafler DA, De Jager PL. Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology. 2013 Nov 26; 81(22):1891-9.
    View in: PubMed
    Score: 0.039
  53. Trentham DE, Dynesius-Trentham RA, Orav EJ, Combitchi D, Lorenzo C, Sewell KL, Hafler DA, Weiner HL. Effects of oral administration of type II collagen on rheumatoid arthritis. Science. 1993 Sep 24; 261(5129):1727-30.
    View in: PubMed
    Score: 0.038
  54. Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y, Herndon R, Lehrich JR, Hauser SL, Turel A, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology. 1993 May; 43(5):910-8.
    View in: PubMed
    Score: 0.037
  55. Oettinger HF, al-Sabbagh A, Jingwu Z, LaSalle JM, Weiner HL, Hafler DA. Biological activity of recombinant human myelin basic protein. J Neuroimmunol. 1993 May; 44(2):157-62.
    View in: PubMed
    Score: 0.037
  56. Hafler DA, Zhang JW, LaSalle J, Donnelly C, Weiner HL, Wucherpfeffnig K. The development of antigen specific therapies for autoimmune diseases; investigations in multiple sclerosis as a paradigm for rheumatoid arthritis. Clin Exp Rheumatol. 1993 Mar-Apr; 11 Suppl 8:S39-40.
    View in: PubMed
    Score: 0.037
  57. Ottoboni L, Keenan BT, Tamayo P, Kuchroo M, Mesirov JP, Buckle GJ, Khoury SJ, Hafler DA, Weiner HL, De Jager PL. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med. 2012 Sep 26; 4(153):153ra131.
    View in: PubMed
    Score: 0.036
  58. Zhang J, Weiner HL, Hafler DA. Autoreactive T cells in multiple sclerosis. Int Rev Immunol. 1992; 9(3):183-201.
    View in: PubMed
    Score: 0.034
  59. Miller A, Hafler DA, Weiner HL. Immunotherapy in autoimmune diseases. Curr Opin Immunol. 1991 Dec; 3(6):936-40.
    View in: PubMed
    Score: 0.034
  60. Miller A, Hafler DA, Weiner HL. Tolerance and suppressor mechanisms in experimental autoimmune encephalomyelitis: implications for immunotherapy of human autoimmune diseases. FASEB J. 1991 Aug; 5(11):2560-6.
    View in: PubMed
    Score: 0.033
  61. Wucherpfennig KW, Weiner HL, Hafler DA. T-cell recognition of myelin basic protein. Immunol Today. 1991 Aug; 12(8):277-82.
    View in: PubMed
    Score: 0.033
  62. Brod SA, al-Sabbagh A, Sobel RA, Hafler DA, Weiner HL. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin antigens: IV. Suppression of chronic relapsing disease in the Lewis rat and strain 13 guinea pig. Ann Neurol. 1991 Jun; 29(6):615-22.
    View in: PubMed
    Score: 0.033
  63. Lee SJ, Wucherpfennig KW, Brod SA, Benjamin D, Weiner HL, Hafler DA. Common T-cell receptor V beta usage in oligoclonal T lymphocytes derived from cerebrospinal fluid and blood of patients with multiple sclerosis. Ann Neurol. 1991 Jan; 29(1):33-40.
    View in: PubMed
    Score: 0.032
  64. Gross R, Healy BC, Cepok S, Chitnis T, Khoury SJ, Hemmer B, Weiner HL, Hafler DA, De Jager PL. Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol. 2011 Apr; 233(1-2):168-74.
    View in: PubMed
    Score: 0.031
  65. Khoury SJ, Healy BC, Kivisäkk P, Viglietta V, Egorova S, Guttmann CR, Wedgwood JF, Hafler DA, Weiner HL, Buckle G, Cook S, Reddy S. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Arch Neurol. 2010 Sep; 67(9):1055-61.
    View in: PubMed
    Score: 0.031
  66. Healy BC, Liguori M, Tran D, Chitnis T, Glanz B, Wolfish C, Gauthier S, Buckle G, Houtchens M, Stazzone L, Khoury S, Hartzmann R, Fernandez-Vina M, Hafler DA, Weiner HL, Guttmann CR, De Jager PL. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology. 2010 Aug 17; 75(7):634-40.
    View in: PubMed
    Score: 0.031
  67. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature. 1990 Jul 12; 346(6280):183-7.
    View in: PubMed
    Score: 0.031
  68. Wucherpfennig KW, Ota K, Endo N, Seidman JG, Rosenzweig A, Weiner HL, Hafler DA. Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. Science. 1990 May 25; 248(4958):1016-9.
    View in: PubMed
    Score: 0.030
  69. Chofflon M, González V, Weiner HL, Hafler DA. Inflammatory cerebrospinal fluid T cells have activation requirements characteristic of CD4+CD45RA- T cells. Eur J Immunol. 1989 Oct; 19(10):1791-5.
    View in: PubMed
    Score: 0.029
  70. De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, Aggarwal NT, Piccio L, Raychaudhuri S, Tran D, Aubin C, Briskin R, Romano S, Baranzini SE, McCauley JL, Pericak-Vance MA, Haines JL, Gibson RA, Naeglin Y, Uitdehaag B, Matthews PM, Kappos L, Polman C, McArdle WL, Strachan DP, Evans D, Cross AH, Daly MJ, Compston A, Sawcer SJ, Weiner HL, Hauser SL, Hafler DA, Oksenberg JR. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet. 2009 Jul; 41(7):776-82.
    View in: PubMed
    Score: 0.028
  71. Chofflon M, Weiner HL, Morimoto C, Hafler DA. Decrease of suppressor inducer (CD4+2H4+) T cells in multiple sclerosis cerebrospinal fluid. Ann Neurol. 1989 May; 25(5):494-9.
    View in: PubMed
    Score: 0.028
  72. Duby AD, Weiner HL, Benjamin DS, Seidman JG, Hafler DA. Sequestration of virus-specific T cells in the cerebrospinal fluid of a patient with varicella zoster viral meningoencephalitis. J Neuroimmunol. 1989 Mar; 22(1):63-8.
    View in: PubMed
    Score: 0.028
  73. Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, Egorova S, Guttmann CR, Rusche JR, Khoury SJ. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology. 2008 Sep 16; 71(12):917-24.
    View in: PubMed
    Score: 0.027
  74. Chofflon M, Weiner HL, Morimoto C, Hafler DA. Loss of functional suppression is linked to decreases in circulating suppressor inducer (CD4+ 2H4+) T cells in multiple sclerosis. Ann Neurol. 1988 Aug; 24(2):185-91.
    View in: PubMed
    Score: 0.027
  75. Carter JL, Hafler DA, Dawson DM, Orav J, Weiner HL. Immunosuppression with high-dose i.v. cyclophosphamide and ACTH in progressive multiple sclerosis: cumulative 6-year experience in 164 patients. Neurology. 1988 Jul; 38(7 Suppl 2):9-14.
    View in: PubMed
    Score: 0.027
  76. Sobel RA, Hafler DA, Castro EE, Morimoto C, Weiner HL. The 2H4 (CD45R) antigen is selectively decreased in multiple sclerosis lesions. J Immunol. 1988 Apr 01; 140(7):2210-4.
    View in: PubMed
    Score: 0.026
  77. Carter JL, Dawson DM, Hafler DA, Fallis RJ, Stazzone L, Orav J, Weiner HL. Cumulative experience with high-dose intravenous cyclophosphamide and ACTH therapy in chronic progressive multiple sclerosis. Ann N Y Acad Sci. 1988; 540:535-6.
    View in: PubMed
    Score: 0.026
  78. Sobel RA, Hafler DA, Castro EE, Morimoto C, Weiner HL. Immunohistochemical analysis of suppressor-inducer and helper-inducer T cells in multiple sclerosis brain tissue. Ann N Y Acad Sci. 1988; 540:306-8.
    View in: PubMed
    Score: 0.026
  79. Chofflon M, Weiner HL, Hafler DA. Loss of functional suppression is linked to decreases in circulating suppressor-inducer (CD4+ 2H4+) T cells in multiple sclerosis. Ann N Y Acad Sci. 1988; 540:330-2.
    View in: PubMed
    Score: 0.026
  80. Dawson DM, Carter JL, Hafler DA, Weiner HL. Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies. Riv Neurol. 1987 Mar-Apr; 57(2):88-91.
    View in: PubMed
    Score: 0.024
  81. Johnson D, Hafler DA, Fallis RJ, Lees MB, Brady RO, Quarles RH, Weiner HL. Cell-mediated immunity to myelin-associated glycoprotein, proteolipid protein, and myelin basic protein in multiple sclerosis. J Neuroimmunol. 1986 Nov; 13(1):99-108.
    View in: PubMed
    Score: 0.024
  82. Cai G, Karni A, Oliveira EM, Weiner HL, Hafler DA, Freeman GJ. PD-1 ligands, negative regulators for activation of naive, memory, and recently activated human CD4+ T cells. Cell Immunol. 2004 Aug; 230(2):89-98.
    View in: PubMed
    Score: 0.020
  83. Tardieu M, Powers ML, Hafler DA, Hauser SL, Weiner HL. Autoimmunity following viral infection: demonstration of monoclonal antibodies against normal tissue following infection of mice with reovirus and demonstration of shared antigenicity between virus and lymphocytes. Eur J Immunol. 1984 Jun; 14(6):561-5.
    View in: PubMed
    Score: 0.020
  84. Weiner HL, Hafler DA, Fallis RJ, Johnson D, Ault KA, Hauser SL. Altered blood T-cell subsets in patients with multiple sclerosis. J Neuroimmunol. 1984 Apr; 6(2):115-21.
    View in: PubMed
    Score: 0.020
  85. Weiner HL, Hauser SL, Hafler DA, Fallis RJ, Lehrich JR, Dawson DM. The use of cyclophosphamide in the treatment of multiple sclerosis. Ann N Y Acad Sci. 1984; 436:373-81.
    View in: PubMed
    Score: 0.019
  86. Weiner HL, Hafler DA, Fallis RJ, Johnson D, Ault KA, Hauser SL. T cell subsets in patients with multiple sclerosis. An overview. Ann N Y Acad Sci. 1984; 436:281-93.
    View in: PubMed
    Score: 0.019
  87. Nussenblatt RB, Gery I, Weiner HL, Ferris FL, Shiloach J, Remaley N, Perry C, Caspi RR, Hafler DA, Foster CS, Whitcup SM. Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am J Ophthalmol. 1997 May; 123(5):583-92.
    View in: PubMed
    Score: 0.012
  88. Morimoto C, Hafler DA, Weiner HL, Letvin NL, Hagan M, Daley J, Schlossman SF. Selective loss of the suppressor-inducer T-cell subset in progressive multiple sclerosis. Analysis with anti-2H4 monoclonal antibody. N Engl J Med. 1987 Jan 08; 316(2):67-72.
    View in: PubMed
    Score: 0.006
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.